Sep 2026
Abstract B144: MUC16-directed DR5 activation by IMV-M induces selective tumor cell apoptosis and tumor regression and enhances the activity of KRAS inhibitors in preclinical pancreatic cancer models
It is demonstrated that IMV-M exhibits potent and selective antitumor activity against MUC16-positive pancreatic cancer models through targeted DR5 activation, supporting the potential development of combination regimens with KRAS-directed therapies that have demonstrated promising clinical activity in pancreatic cance...
Hai-Yong Han, M. Zucker, Sanjana Tripuraneni et al.
· Cancer Research · 0 citations